1. The general aim of this proposal is to realize the scientific potential of the newly formed Pediatric Oncology Group (POG). Investigators at Oklahoma will continue our research in oncology by registering patients on POG and intergroup protocols, to continue to write protocols for POG, to continue to pilot protocols, and to continue to analyze data and generate manuscripts and abstracts. Specific activities of investigators at Oklahoma done for POG include; 2. To continue to redefine subgroups within acute lymphoblastic leukemia (ALL) that have prognostic significance. We will periodically analyze acummulating data from our tumor marker studies (ALinC 13). The following need to be periodically analyzed: the prognostic significance of a complement receptor on null and pre B cells, the thermal stability of the E receptor and T cell ALL, the relative prognostic significance of T antigen positive and E receptor positive T ALL, the significance at diagnosis of circulating normal T cells or activated T cells in null cell and pre B cell ALL, etc. 3. To attempt to improve the therapeutic outcome and better define central nervous system tumors by evaluating the therapeutic efficacy of cis-platinum and by studying tumor markers such as polyamines. 4. To attempt to apply tumor biology to human solid tumors in order to better define prognostic subgroups, to predict metastatic potential, etc. This involves a feasibility study to determine if solid tumors from member institutions can be mailed to Oklahoma for dissociation and cryopreservation in order to establish a solid tumor bank. 5. To increase the role of bone marrow transplantation in the management of leukemic children who have a poor prognosis. This will include not only sibling transplants but a program for parent to child bone marrow transplantation, initially for leukemic cases at Oklahoma and then as a POG protocol. 6. To establish a more accurate method of diagnosing meningeal leukemia using TdT. 7. A comprehensive evaluation of all stages of neuroblastoma. 8. To determine if viral infections at the time of diagnosis have prognostic significance with regard to immunosuppressive viruses such as CMV and EBV. 9. To provide leadership and serve the administrative needs of POG. Investigators at Oklahoma are involved in a number of scientific and administrative committees for POG.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA011233-17
Application #
3555971
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Project Start
1978-01-01
Project End
1986-01-31
Budget Start
1985-01-01
Budget End
1986-01-31
Support Year
17
Fiscal Year
1985
Total Cost
Indirect Cost
Name
University of Oklahoma Health Sciences Center
Department
Type
Schools of Medicine
DUNS #
937727907
City
Oklahoma City
State
OK
Country
United States
Zip Code
73117
Gilbert, M Melissa; Tipping, Marla; Veraksa, Alexey et al. (2011) A screen for conditional growth suppressor genes identifies the Drosophila homolog of HD-PTP as a regulator of the oncoprotein Yorkie. Dev Cell 20:700-12
Wacker, Pierre; Land, Vita J; Camitta, Bruce M et al. (2007) Allergic reactions to E. coli L-asparaginase do not affect outcome in childhood B-precursor acute lymphoblastic leukemia: a Children's Oncology Group Study. J Pediatr Hematol Oncol 29:627-32
Chintharlapalli, Sudhakar; Papineni, Sabitha; Jutooru, Indira et al. (2007) Structure-dependent activity of glycyrrhetinic acid derivatives as peroxisome proliferator-activated receptor {gamma} agonists in colon cancer cells. Mol Cancer Ther 6:1588-98
Chintharlapalli, Sudhakar; Papineni, Sabitha; Baek, Seung Joon et al. (2005) 1,1-Bis(3'-indolyl)-1-(p-substitutedphenyl)methanes are peroxisome proliferator-activated receptor gamma agonists but decrease HCT-116 colon cancer cell survival through receptor-independent activation of early growth response-1 and nonsteroidal anti-infl Mol Pharmacol 68:1782-92
Ravindranath, Y; Chang, M; Steuber, C P et al. (2005) Pediatric Oncology Group (POG) studies of acute myeloid leukemia (AML): a review of four consecutive childhood AML trials conducted between 1981 and 2000. Leukemia 19:2101-16
Shamberger, Robert C; LaQuaglia, Michael P; Gebhardt, Mark C et al. (2003) Ewing sarcoma/primitive neuroectodermal tumor of the chest wall: impact of initial versus delayed resection on tumor margins, survival, and use of radiation therapy. Ann Surg 238:563-7; discussion 567-8
Goorin, Allen M; Schwartzentruber, Douglas J; Devidas, Meenakshi et al. (2003) Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: Pediatric Oncology Group Study POG-8651. J Clin Oncol 21:1574-80
Lacayo, N J; Lum, B L; Becton, D L et al. (2002) Pharmacokinetic interactions of cyclosporine with etoposide and mitoxantrone in children with acute myeloid leukemia. Leukemia 16:920-7
Laver, Joseph H; Mahmoud, Hazem; Pick, Terry E et al. (2002) Results of a randomized phase III trial in children and adolescents with advanced stage diffuse large cell non-Hodgkin's lymphoma: a Pediatric Oncology Group study. Leuk Lymphoma 43:105-9
Saylors 3rd, R L; Stine, K C; Sullivan, J et al. (2001) Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study. J Clin Oncol 19:3463-9

Showing the most recent 10 out of 31 publications